Skip to main content
. Author manuscript; available in PMC: 2014 Dec 1.
Published in final edited form as: Clin Cancer Res. 2013 Dec 1;19(23):10.1158/1078-0432.CCR-13-0734. doi: 10.1158/1078-0432.CCR-13-0734

Figure 1. Mab both increase Type I cells in the breast cancer microenvironment and “auto vaccinate”.

Figure 1

(A) Dependent on the antibody isotype, mAb can fix complement resulting in direct lysis of cells to which the antibody binds. (B) Many mAb mediate ADCC, the recruitment of NK and other immune system cells to the tumor via Fc receptor binding. NK cells are a major source of secreted IFN-g which activates APC. (C) Antigen shed by tumor lysis is taken up by the activated APC and presented to T-cells, stimulating Th1 and CTL in the IFN-g rich microenvironment.